translation agency

NLM AIDSLINE
Antibody responses to influenza vaccines in HIV infected patients.
Baldelli F; Francisci D; Iorio A; Zei T; Salvatori M; Stagni G;
December 30, 1992
Int Conf AIDS. 1992 Jul 19-24;8(3):53 (abstract no. PuB 7025). Unique

OBJECTIVES: To ascertain the development of protective hemagglutination inhibition antibody responses to inactivated influenza vaccines in patients infected with HIV. MATERIALS AND METHODS: 49 subjects were immunized with trivalent influenza vaccine (A/Beijing 353/89; A/Singapore 6/85; B/Yamagata 16/88). Nineteen were HIV+ (11 asystomatic, 7 ARC, 2 AIDS), 30 were seronegative controls without risk factors and of the same age. IHA was performed simultaneously in pre and post (30 days after each doses) sera by standard microtiter method. Protection rate was evaluated as number of people exceeding the threshold titre of 1:40. Protective response rate was evaluated as number of people with a development of protective antibody levels after immunization. RESULTS: After vaccination the protection rate in seropositive patients and controls was respectively 42% and 64% for H1N1. 89% and 90% for H3N2, 73% and 66% for B influenza virus. The protective response rate in HIV pts. and controls for H1N1 was 38% and 50%, for H3N2 71% and 83%, for B influenza virus 79% and 54%. Due to small numbers, results are not conventionally statistically significant, yet odds ratios show interesting trends: the risk for HIV patients of not developing a protective response was 1.57 for H1N1, 2.0 for H3N2, but only 0.46 for B. We didn't observe any difference in CD4 count and P 24 antigenemia before and after vaccination. CONCLUSIONS: In any case this vaccination is to be recommended, especially in pts. living in community, because it is useful and harmless.

Antibodies, Viral/*BIOSYNTHESIS Hemagglutination Inhibition Tests Human HIV Infections/*IMMUNOLOGY Influenza Vaccine/*IMMUNOLOGY Orthomyxoviridae/*IMMUNOLOGY Vaccination Vaccines, Inactivated/IMMUNOLOGY ABSTRACT

www.aegis.org